Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:MUSA
NYSE:MUSASpecialty Retail

What Murphy USA (MUSA)'s CFO Appointment and Governance Moves Mean For Shareholders

On March 26, 2026, Murphy USA announced that long-time finance executive Donald R. Smith, Jr. had been appointed permanent Senior Vice President, Chief Financial Officer and Treasurer, while also disclosing his compensation terms and related governance details. This leadership change highlights the board’s preference for continuity and internal expertise at a time when some shareholders are also pushing for greater influence over corporate governance. We’ll now examine how Smith’s elevation...
NasdaqGS:TECH
NasdaqGS:TECHLife Sciences

How Bio-Techne's Spatial Biology COMET Expansion (TECH) Has Changed Its Investment Story

In March 2026, Bio-Techne expanded its COMET spatial biology portfolio with new SPYRE Focus Panels, SPYRE Amplification Kits, and upgraded HORIZON image analysis software to enhance automated, modular tissue analysis workflows from assay design through interpretation. This expansion deepens Bio-Techne’s footprint in high-content spatial biology by combining validated, modular antibody panels with seqLA-based signal amplification to help researchers extract richer insights from scarce tissue...
NasdaqCM:RGC
NasdaqCM:RGCPharmaceuticals

Assessing Regencell Bioscience Holdings (NasdaqCM:RGC) Valuation After New Equity Offering Plans

Why Regencell Bioscience Holdings (NasdaqCM:RGC) is in Focus Right Now Regencell Bioscience Holdings (NasdaqCM:RGC) has filed a US$500 million follow on equity offering of common stock as an at the market program, shortly after registering a shelf for its ordinary shares. See our latest analysis for Regencell Bioscience Holdings. The equity offering headlines come after a sharp shift in sentiment, with a 7 day share price return of 32.15% and a 30 day share price return of 32.03%, set against...
NYSE:TPB
NYSE:TPBTobacco

A Look At Turning Point Brands (TPB) Valuation After FDA Delays On Nicotine Pouch Approvals

Turning Point Brands (TPB) is back in focus after reports that the FDA is delaying approvals for its nicotine pouch products, raising fresh questions around regulation, youth access, and future product launches. See our latest analysis for Turning Point Brands. The regulatory headlines have hit sentiment hard, with a 30 day share price return showing an 18.51% decline and a 90 day share price return showing a 27.63% decline, even after the recent 3.51% one day gain to US$74.69. However, the 1...
NYSE:KVUE
NYSE:KVUEPersonal Products

Kenvue’s Dermatologist-Focused Skincare Push Might Change The Case For Investing In Kenvue (KVUE)

At the March 27–31, 2026 American Academy of Dermatology meeting in Denver, Kenvue’s Neutrogena, Aveeno, and Rogaine brands showcased new science-backed products, research on hydration, acne care, and sun protection, and educational initiatives for dermatology professionals and residents. The breadth of clinical data, including work on advanced UV filters like BEMT and skin-barrier-supportive formulations, highlights how Kenvue is tying product innovation directly to evolving dermatologist...
NYSE:NNI
NYSE:NNIConsumer Finance

Does Nelnet’s New Long-Dated Credit Line Reveal a Shift in Funding Strategy for NNI?

Nelnet, Inc. recently entered into a new Credit Agreement for a US$435 million unsecured line of credit maturing on March 31, 2031, while terminating its prior US$495 million facility that was due in 2026 and carried no outstanding balance at the time. This refreshed, long-dated borrowing capacity, backed by customary financial covenants and subsidiary guarantees, underscores the company’s emphasis on maintaining flexible funding for general corporate purposes. With this extended US$435...
NYSE:DINO
NYSE:DINOOil and Gas

Does Repeated Earnings Outperformance Reshape The Profit Narrative For HF Sinclair (DINO)?

Recently, HF Sinclair reported quarterly earnings of US$1.20 per share, very large above the consensus estimate of US$0.44, extending a multi-quarter pattern of outperforming analyst expectations. This repeated earnings outperformance has led analysts to grow more optimistic about the company’s near‑term profit potential, especially given its integrated refining and fuel production footprint. Building on this recent history of substantial earnings surprises, we’ll explore how strengthened...
CPSE:CARL B
CPSE:CARL BBeverage

Carlsberg (CPSE:CARL B) Valuation Check After Recent Share Price Gains Without Clear News Catalyst

Carlsberg stock reaction and recent performance snapshot Carlsberg (CPSE:CARL B) has moved without a clear single news catalyst. This has left investors to focus on recent share performance, valuation signals and the company’s latest reported financial profile. Over the past month, the share price shows a return of about 10%, while the past 3 months are roughly flat. Year to date, Carlsberg’s total return is around 1% lower, with a 1 year total return close to 1%. See our latest analysis for...
NasdaqGS:ICLR
NasdaqGS:ICLRLife Sciences

How ICON’s AI-Focused Partnership with Advarra Could Reshape ICLR’s Clinical Trial Efficiency Narrative

In March 2026, ICON plc and Advarra announced a partnership to create a connected, “research-ready” site network that links ICON’s clinical trial solutions with Advarra’s widely used site technologies to reduce administrative friction, speed up study startup, and expand trial access globally. This collaboration gives ICON access to Advarra’s data and AI-driven operational intelligence, potentially refining protocol design, forecasting, and site selection by aligning studies more closely with...
NasdaqGS:ARQT
NasdaqGS:ARQTBiotechs

Why Arcutis Biotherapeutics (ARQT) Is Up 10.9% After Positive Infant Atopic Dermatitis Trial Data And What's Next

At the 2026 American Academy of Dermatology meeting in Denver, Arcutis Biotherapeutics reported Phase 2 INTEGUMENT-INFANT data showing ZORYVE cream 0.05% improved signs and symptoms of mild to moderate atopic dermatitis in infants aged 3 to less than 24 months, with a safety and tolerability profile consistent with prior pediatric trials. Beyond reinforcing ZORYVE’s safety across very young patients, the new data underpin Arcutis’ plan to file a supplemental New Drug Application in 2026,...
NasdaqGS:PAYP
NasdaqGS:PAYPDiversified Financial

A Look At PayPay (PAYP) Valuation After Recent Share Price Pullback

Key performance context for PayPay PayPay (PAYP) has drawn attention after a 10.37% one day decline and an 8.81% drop over the past week, prompting investors to reassess its fundamentals and recent share price moves. The company reports annual revenue of ¥355,530 and net income of ¥111,208, with revenue growth of 16.82% and net income growth of 5.77% in the most recent year, all in its reporting currency. See our latest analysis for PayPay. The recent 10.37% one day share price return decline...
SEHK:175
SEHK:175Auto

Geely Automobile Holdings (SEHK:175) Valuation After Volvo Lynk & Co Importer Agreement For Europe

Geely Automobile Holdings (SEHK:175) is back in focus after Volvo Cars and Geely Auto signed a memorandum of understanding that would make Volvo the exclusive importer and commercial operator for Lynk & Co vehicles in Europe. See our latest analysis for Geely Automobile Holdings. The memorandum of understanding appears to have arrived at a time when momentum in Geely Automobile Holdings' shares has been strong, with a 1 month share price return of 45.60% and a year to date share price return...
ASX:4DX
ASX:4DXHealthcare Services

EU CT:VQ Approval And A$83m Raise Might Change The Case For Investing In 4DMedical (ASX:4DX)

4DMedical Limited recently completed an A$83,000,002 follow-on equity offering at A$5.90 per share, shortly after announcing that its CT:VQ imaging technology had received CE Mark certification for commercial use across the European Union. The CE Mark for CT:VQ gives 4DMedical access to one of the world’s largest respiratory imaging markets, leveraging existing CT infrastructure without needing radiotracers or specialised nuclear medicine facilities. We’ll now examine how EU commercial...
NasdaqGM:MAAS
NasdaqGM:MAASInsurance

Assessing Maase (MAAS) Valuation After Recent Short Term Share Price Gains

Why Maase Has Caught Investor Attention Recent trading interest in Maase (MAAS) has pushed the stock into focus, with short term performance and fundamentals prompting investors to reassess how this US listed China based financial services platform fits into their portfolios. See our latest analysis for Maase. At a share price of $5.90, Maase has seen a 7 day share price return of 8.26% and a 90 day share price return of 13.24%, suggesting recent momentum is building after a relatively modest...
TSE:4307
TSE:4307IT

Assessing Nomura Research Institute (TSE:4307) Valuation After Recent Share Weakness And Growth Outlook

Recent share performance and business mix With no single headline event driving Nomura Research Institute (TSE:4307) today, investors may be looking at the share price moves and business mix to understand what is shaping sentiment around the stock. The company’s shares show a 0.2% gain over the past day and about 3.4% over the past week, while the past month return is around 2%. Over the past 3 months, the stock shows a 26.9% decline and the return so far this year is a 25.6% decline. Over...
TSE:8056
TSE:8056IT

A Look At BIPROGY (TSE:8056) Valuation As It Expands Into Energy Aggregation And Power Assets

BIPROGY (TSE:8056) has put a proposal on the table to amend its Articles of Incorporation so it can own and operate electric power and storage assets, and run energy aggregation services. See our latest analysis for BIPROGY. The proposed move into energy aggregation comes after a mixed year in the market, with BIPROGY’s recent 30 day share price return of 2.08% following a 90 day share price decline of 13.26%. The 1 year total shareholder return sits at 12.20%, which indicates that longer...
TSX:BBD.B
TSX:BBD.BAerospace & Defense

A Look At Bombardier (TSX:BBD.B) Valuation After First Global 8000 Delivery To NetJets

Bombardier (TSX:BBD.B) has delivered the first Global 8000 jet to long term partner NetJets, the fleet launch customer that plans a lineup of 24 aircraft and upgrades of existing Global 7500 jets. See our latest analysis for Bombardier. The Global 8000 delivery and recent debt consent process come as Bombardier’s share price sits at CA$252.16, with short term share price returns in the low to mid single digits and very strong multi year total shareholder returns, suggesting momentum has been...
NasdaqCM:CLSK
NasdaqCM:CLSKSoftware

A Look At CleanSpark (CLSK) Valuation After $100 Million Bitcoin Backed Bond Decision

CleanSpark (CLSK) is drawing fresh attention after approving a US$100 million bitcoin backed bond issue to fund data centers and power assets, a financing step aimed at expanding its bitcoin mining infrastructure. See our latest analysis for CleanSpark. The bitcoin backed bond announcement comes after a weaker patch for the shares, with a 90 day share price return of a 24.1% decline and a year to date share price return of a 21.21% decline, alongside a 1 year total shareholder return of...
NYSE:GLW
NYSE:GLWElectronic

Corning (GLW) Valuation Check After Major Meta AI Data Center Cable Expansion

AI data center buildout puts Corning in the spotlight Corning (GLW) is back on investors’ radar after breaking ground on a major expansion of its optical cable production in Hickory, North Carolina, tied to a multiyear supply agreement of up to US$6b with Meta Platforms. See our latest analysis for Corning. The Meta agreement and AI data center expansion have arrived alongside a strong price run, with Corning’s 90 day share price return of 64.15% and 1 year total shareholder return of 275.43%...
NYSE:FIHL
NYSE:FIHLInsurance

A Look At Fidelis Insurance Holdings (FIHL) Valuation As Analysts See Shares 11% Below Fair Value

FIHL stock moves and recent financial snapshot Fidelis Insurance Holdings (FIHL) has seen its share price show modest short term moves, with a 1 day return of 0.78% and a past month return of 3.6%. These recent moves may prompt some investors to take a closer look at its fundamentals. The company reports annual revenue of US$2,500.5m and net income of US$225.5m. This implies a net margin figure that investors can compare with other insurers. Annual revenue growth is reported at 11.7%, with...
NYSE:AIR
NYSE:AIRAerospace & Defense

Assessing AAR (AIR) Valuation After Q3 Beat Higher Guidance And New U.S. Air Force Contracts

AAR (AIR) is back in focus after a packed March, with third quarter earnings, higher full year sales guidance, and two long term U.S. Air Force pallet contracts worth up to $450 million. See our latest analysis for AAR. The recent 3.8% 1 day share price return and 10.5% 7 day share price return, on top of a 35.0% year to date share price return and 132.8% 1 year total shareholder return, suggest momentum has been building around AAR as investors react to the stronger earnings, higher sales...
NYSE:CXT
NYSE:CXTElectronic

A Look At Crane NXT (CXT) Valuation After Recent Share Price Weakness

Crane NXT overview and recent share performance Crane NXT (CXT) has drawn investor attention after recent share price swings, with the stock up about 3% over the past day but showing negative returns over the month and past 3 months. Over the past month the share price return sits around 10% lower, and over the past 3 months the return is about 17% lower, contributing to a year to date decline of roughly 13%. Looking over a longer window, the stock shows a 1 year total return of about 5%...
ENXTPA:TTE
ENXTPA:TTEOil and Gas

Assessing TotalEnergies (ENXTPA:TTE) Valuation After $2.2b Masdar Renewables Joint Venture Announcement

TotalEnergies (ENXTPA:TTE) has put a fresh spotlight on its share with a binding $2.2b 50/50 joint venture alongside Abu Dhabi based Masdar to combine onshore renewables across nine Asian markets. See our latest analysis for TotalEnergies. The joint venture news comes after a strong run, with a 48.42% 90 day share price return and a 66.82% 1 year total shareholder return. This suggests that momentum has been building despite some recent short term share price volatility. If this kind of...
NYSE:WTS
NYSE:WTSMachinery

Is Watts Water Technologies (WTS) Still Attractive After Recent Pullback And Strong Five Year Run?

If you are wondering whether Watts Water Technologies is priced attractively at its recent levels, the starting point is understanding what the current market price is implying about its future. The share price recently closed at US$287.95, with returns of 1.5% over 7 days, a 5.9% decline over 30 days, 3.4% year to date, 58.6% over 1 year, 87.8% over 3 years, and 151.1% over 5 years. Recent coverage of the company has focused on its role within capital goods and water-related solutions. This...